Menopausal hormone therapies: Their effect on mammographic density and breast cancer risk

Gynecological Endocrinology

Volumn 21, Issue SUPPL. 1, 2005, Pages 12-16

  Santen, Richard ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Breast cancer; Estrogen; Hormone therapy; Mammographic density; Progestogen; Tibolone

Indexed keywords

AROMATASE; ESTRADIOL; ESTROGEN; GESTAGEN; KI 67 ANTIGEN; TAMOXIFEN; TIBOLONE;

BODY DENSITY; BREAST; BREAST CANCER; BREAST EXAMINATION; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAMMOGRAPHY; RISK FACTORS;

EID: 25144450703     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590400030046     Document Type: Conference Paper

References (20)

1. Persson I, Thufjell E, Holmberg L. Effect of estrogen and estrogen progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-3207.
2. Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Söderqvist G, Mol-Arts M, Barkfeldt J, von Schoultz B. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-722.
3. Beral V, the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
4. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253.
5. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-4565.
6. Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids 2003;68:953-964.
7. Harvey JA, Pinkerton JV, Herman CR. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Nat Cancer Inst 1997;89:1623-1625.
8. Boyd NF, Jensen HM, Cooke G, Han HL, Lockwood GA, Miller AB. Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Eur J Cancer Prev 2000;9:15-24.
9. Harvey JA, Bovbjerg VE. Quatitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004;230:29-41.
10. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast density. Cancer Epidemiol Biomarkers Prev 2000;9:911-915.
11. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999;281:2091-2097.
12. Bonnier P, Bessenay F, Sasco AJ, Beedassy B, Lejeune C, Romain S, Charpin C, Piana L, Martin PM. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 1998; 79:278-282.
13. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998;16:3115-3120.
14. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449-457.
15. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN. Estrogen replacement therapy and breast cancer survival in a large screening study. J Nat Cancer Inst 1999;91:264-270.
16. Collaborative Group on Hormone Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059.
17. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
18. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332: 1589-1593.
19. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast cancer risk following long-term oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81:339-44.
20. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23.